However, lowered incidence of high-grade tumours was observed (HR 0.55; 95% CI 0.31–0.96), with a decreasing trend in risk with cumulative duration of alpha-blocker use ( Table 3 ).
← all excerpts
Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial.
1
—
—